Claybrook Capital, LLC Bristol Myers Squibb CO Transaction History

Claybrook Capital, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$72.62 - $79.98 $1.83 Million - $2.02 Million	-25,220 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$61.48 - $73.72 $67,628 - $81,092	-1,100 Reduced 4.18%	25,220 $1.84 Million
Q4 2021 Jan 20, 2022	BUY	$53.63 - $62.52 $1.41 Million - $1.65 Million	26,320 New	26,320 $1.64 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $2.35 Million - $2.75 Million	-39,731 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$61.91 - $67.42 $2.46 Million - $2.68 Million	39,731 New	39,731 $2.65 Million
Q2 2020 Jul 29, 2020	SELL	$54.82 - $64.09 $1.41 Million - $1.64 Million	-25,639 Closed	0 $0
Q1 2020 May 05, 2020	SELL	$46.4 - $67.43 $53,406 - $77,611	-1,151 Reduced 4.3%	25,639 $1.43 Million
Q3 2019 Nov 13, 2019	BUY	$42.77 - $50.71 $42,770 - $50,710	1,000 Added 3.88%	26,790 $1.36 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $98,164 - $108,548	2,200 Added 9.33%	25,790 $1.17 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $1.04 Million - $1.24 Million	23,006 Added 3939.38%	23,590 $1.13 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $292 - $379	-6 Reduced 1.02%	584 $30,000
Q1 2018 May 11, 2018	SELL	$59.92 - $68.98 $280,485 - $322,895	-4,681 Reduced 88.81%	590 $37,000
Q4 2017 May 08, 2018	BUY	$59.94 - $65.35 $315,943 - $344,459	5,271	5,271 $323,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Claybrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Claybrook Capital, LLC with notifications on news.